The FDA-approved eligibility for semaglutide (Wegovy\u00ae) for weight management is BMI \u226530 (obesity) or BMI \u226527 (overweight) with at least one weight-related condition such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea. Compounded semaglutide follows the same general clinical criteria when prescribed by a licensed provider.<\/p>\n
Absolute contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2 (MEN-2), prior serious hypersensitivity to semaglutide, and pregnancy. Relative contraindications include severe gastroparesis, history of pancreatitis, active gallbladder disease, severe renal impairment with dehydration risk, and active eating disorders.<\/p>\n
This article walks through who qualifies, who doesn’t, and the gray-zone cases that need provider judgment.<\/p>\n
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n
Standard eligibility for weight management:<\/p>\n
Quick Answer: FDA-approved BMI cutoffs: \u226530 alone or \u226527 with a weight-related condition<\/p>\n
BMI \u226530 kg\/m\u00b2 (obesity) qualifies regardless of other conditions. For someone 5’8″, that’s about 197 pounds. For 5’4″, about 175 pounds.<\/p>\n
BMI \u226527 kg\/m\u00b2 with at least one weight-related comorbidity qualifies under the “overweight with complications” criterion. Qualifying conditions include type 2 diabetes, prediabetes, hypertension, dyslipidemia, obstructive sleep apnea, fatty liver disease, PCOS, and cardiovascular disease.<\/p>\n
BMI 25-27 without comorbidities falls outside FDA-approved indications. Some clinicians will prescribe off-label for patients in this range who have failed lifestyle interventions, but most reputable telehealth platforms decline this group. TrimRx applies the standard FDA criteria during the free assessment quiz.<\/p>\n
Personal or family history of medullary thyroid carcinoma (MTC) is the strongest contraindication.<\/strong> The boxed warning is based on rodent data showing C-cell tumors with GLP-1 agonists. The relevance to humans remains debated, but the FDA labeling treats it as exclusionary.<\/p>\n Multiple endocrine neoplasia syndrome type 2 (MEN-2) also excludes use. This is a hereditary syndrome that predisposes to medullary thyroid cancer and other endocrine tumors.<\/p>\n Prior serious hypersensitivity to semaglutide or any component of the formulation excludes use. This includes anaphylaxis, angioedema, or severe injection-site reactions.<\/p>\n Pregnancy and active attempts at conception are contraindications. Animal data show fetal harm at clinically relevant doses, and the long half-life means the drug persists for weeks after discontinuation. Stop at least 2 months before conception per manufacturer guidance.<\/p>\n Prior acute pancreatitis is a relative contraindication.<\/strong> Trial exclusion criteria for STEP 1 and SELECT excluded participants with a history of pancreatitis, so safety data in this group is limited. Pooled GLP-1 trial data show pancreatitis rates of about 0.2% on the drug vs 0.1% on placebo, suggesting roughly double the background risk.<\/p>\n For someone with a single prior episode of mild pancreatitis (often gallstone-related) many years ago, semaglutide may still be reasonable with close monitoring. For someone with chronic pancreatitis, recurrent episodes, or pancreatitis triggered by hypertriglyceridemia, semaglutide is generally avoided.<\/p>\n The decision is individualized. A consultation with a gastroenterologist before starting is often advisable for anyone with significant pancreatic history.<\/p>\n Active gallbladder disease, ongoing biliary colic, or recent cholecystitis is a contraindication until the issue is resolved.<\/strong> Semaglutide further slows gallbladder motility and accelerates gallstone formation during rapid weight loss.<\/p>\n Prior cholecystectomy (gallbladder removal) is not a contraindication. People without a gallbladder can take semaglutide normally, sometimes with slightly looser stools as a side note.<\/p>\n Known asymptomatic gallstones occupy a gray zone. Some clinicians treat them and recommend semaglutide; others monitor and start anyway. STEP trial data showed gallbladder events in 2.6% on semaglutide vs 1.2% on placebo. The absolute risk is low but real.<\/p>\n Mild to moderate CKD (eGFR 30-90) does not exclude semaglutide.<\/strong> The FLOW trial (Perkovic 2024, NEJM) specifically tested semaglutide in CKD and showed benefit, including in stage 3-4 disease.<\/p>\n Severe CKD (eGFR <30) is a relative contraindication. Limited safety data, slowed drug clearance, and higher dehydration risk from GI side effects all argue for caution. Some patients in this range still benefit, but monitoring and hydration discipline are essential.<\/p>\n ESRD on dialysis falls outside trial data. Use in this group is not recommended without specialist input.<\/p>\n Wegovy is FDA-approved for adolescents ages 12-17 with BMI \u226595th percentile, based on the STEP TEENS trial (Kelly 2022, NEJM) which showed 16.1% weight loss at 68 weeks vs 0.6% on placebo.<\/strong> Pediatric prescribing should be through specialized adolescent obesity programs, not standard telehealth.<\/p>\n For older adults, semaglutide is approved and effective into the 70s and 80s. The SELECT trial included participants up to age 85 and showed benefit. Concerns in older patients include sarcopenia risk (preserve protein and strength training), polypharmacy interactions, and dehydration sensitivity. The benefits often outweigh risks, especially for cardiovascular indication.<\/p>\n The 65+ population doesn’t need a different dose, but slower titration is often appropriate to minimize GI side effects.<\/p>\n Active anorexia nervosa, bulimia nervosa, or binge eating disorder (severe) are contraindications.<\/strong> Semaglutide’s appetite suppression can amplify restrictive eating patterns or mask the disordered behavior pattern without addressing it.<\/p>\n History of remitted eating disorder requires clinical judgment. Many patients with binge eating disorder in remission tolerate semaglutide well and find it actually reduces binge urges. People with restrictive eating histories are higher risk.<\/p>\n Working with a mental health provider experienced in eating disorders alongside the prescribing clinician is the safest approach for anyone with this history.<\/p>\n Key Takeaway: Pregnancy is a contraindication; stop at least 2 months before attempting conception<\/p>\n Insulin and sulfonylureas (glipizide, glimepiride) require dose reduction when adding semaglutide to avoid hypoglycemia.<\/strong> Concurrent use is allowed but needs glucose monitoring.<\/p>\n Warfarin and other narrow-therapeutic-index oral medications may have altered absorption due to slowed gastric emptying. INR monitoring after starting semaglutide is standard for warfarin patients.<\/p>\n Levothyroxine absorption can decrease with semaglutide. Take levothyroxine on an empty stomach 30-60 minutes before any food or other medication, and recheck TSH 6-8 weeks after starting semaglutide.<\/p>\n There are no absolute drug-drug exclusions, but a full medication review is part of standard eligibility evaluation.<\/p>\n No standard exclusions exist for body composition.<\/strong> Athletes with high muscle mass and BMI \u226530 from muscle (not fat) are technically eligible, though most don’t seek semaglutide because BMI overstates their fat mass.<\/p>\n Type 1 diabetes is not FDA-approved for semaglutide, but off-label use in T1D for weight loss or insulin reduction is increasingly common with endocrinology supervision. Concerns include hypoglycemia and ketoacidosis with significant dose reductions of insulin.<\/p>\n Prior bariatric surgery is not a contraindication. Many post-bariatric patients use semaglutide for weight regain. Doses and titration may be modified.<\/p>\n Standard intake includes:<\/p>\n Telehealth platforms like TrimRx conduct this through structured intake forms followed by provider review. The free assessment quiz captures the relevant clinical information for an initial determination. A licensed provider then approves, requests additional information, or declines the prescription.<\/p>\n For adults over 65, semaglutide remains effective and is increasingly used given the cardiovascular and metabolic benefits.<\/strong> The SELECT trial included participants up to 85, and demonstrated benefit across age groups.<\/p>\n Concerns specific to older adults:<\/p>\n Sarcopenia risk is higher. Protein intake of 1.5-2.0 g\/kg\/day and regular resistance training are even more important than in younger adults. Without these, the muscle component of weight loss can accelerate functional decline.<\/p>\n Polypharmacy is common. Medication reviews are essential. Levothyroxine, warfarin, and insulin dose adjustments are more common in this group.<\/p>\n Dehydration sensitivity is higher. Older adults often have blunted thirst response and may not drink enough during GI side effects. Aggressive hydration counsel is appropriate.<\/p>\n Falls from orthostatic hypotension can occur as blood pressure drops on treatment combined with antihypertensives. Standing BP checks during titration reduce fall risk.<\/p>\n Depression and anxiety are common in patients with obesity and don’t exclude semaglutide.<\/strong> Stable treatment with SSRIs, SNRIs, bupropion, or other agents is compatible with GLP-1 therapy.<\/p>\n Bipolar disorder and schizophrenia don’t exclude semaglutide. In fact, many patients in these populations need GLP-1 therapy specifically to counteract antipsychotic-associated weight gain. Coordination with psychiatric care is appropriate.<\/p>\n Active substance use disorder is a relative consideration. Alcohol use disorder is being studied as a potential indication for GLP-1 drugs, but unstable active addiction can complicate adherence and side-effect management.<\/p>\n Elevated lipase or amylase without symptoms of pancreatitis: usually doesn’t exclude semaglutide but warrants further investigation before starting.<\/strong><\/p>\n Mild liver function abnormalities (transaminases up to 3x normal): generally don’t exclude semaglutide. The drug is studied in MASH and improves liver outcomes.<\/p>\n Severe liver disease (Child-Pugh class C cirrhosis): exclude.<\/p>\n Severe kidney impairment (eGFR <15): exclude in most cases. eGFR 15-30 needs cautious clinical judgment.<\/p>\n Bottom line: Age guidance: FDA approved for adults; expanded to ages 12-17 for Wegovy in late 2022<\/p>\n Generally not through FDA-approved pathways. BMI <27 falls outside indication. Some off-label prescribing happens, but reputable platforms apply the BMI \u226530 (or \u226527 with comorbidity) standard.<\/p>\n Yes for most clinical purposes. PCOS is well-established as a weight-related metabolic condition associated with insulin resistance, and semaglutide is increasingly used for PCOS management.<\/p>\n A benign thyroid nodule without family or personal history of medullary thyroid cancer doesn’t exclude semaglutide. Discuss with an endocrinologist if the nodule has concerning features or rapid growth.<\/p>\n Yes. Prior cholecystectomy is not a contraindication. You may have slightly looser stools as a baseline, which can be amplified mildly by semaglutide.<\/p>\n Yes. There are no major drug-drug interactions between semaglutide and SSRIs, SNRIs, bupropion, or other common psychiatric medications. Mood monitoring is reasonable for anyone with prior depression history.<\/p>\n Most reputable platforms require recent labs within 6-12 months including A1c, basic metabolic panel, and lipids. Some additionally check thyroid function or lipase based on risk factors. TrimRx confirms required labs as part of the personalized treatment plan.<\/p>\n Most basic eligibility labs are inexpensive at direct-to-consumer labs like Quest or LabCorp ($50-$150 cash for the full panel). Telehealth platforms often partner with these labs for affordable testing.<\/p>\n Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n <\/p>\n Introduction The FDA-approved eligibility for semaglutide (Wegovy\u00ae) for weight management is BMI \u226530 (obesity) or BMI \u226527 (overweight) with at least one weight-related condition…<\/p>\n","protected":false},"author":11,"featured_media":92686,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"Compounded Semaglutide Who Should (and Shouldn't) Take It: Eligibility & Contraindications","_yoast_wpseo_metadesc":"The FDA-approved eligibility for semaglutide (Wegovy\u00ae) for weight management is BMI \u226530 (obesity) or BMI \u226527 (overweight) with at least one...","_yoast_wpseo_focuskw":"compounded semaglutide eligibility","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[7],"tags":[22,46],"class_list":["post-89315","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-semaglutide","tag-compounded","tag-semaglutide"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/89315","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=89315"}],"version-history":[{"count":4,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/89315\/revisions"}],"predecessor-version":[{"id":93687,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/89315\/revisions\/93687"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/92686"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=89315"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=89315"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=89315"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}What About Pancreatitis History?<\/h2>\n
How Does Gallbladder Disease Affect Eligibility?<\/h2>\n
What About Kidney Disease?<\/h2>\n
Can Teens or Older Adults Use Semaglutide?<\/h2>\n
What About Eating Disorders?<\/h2>\n
What Medications Interact with Eligibility?<\/h2>\n
Are There Body Composition or Metabolic Exclusions?<\/h2>\n
What Does the Eligibility Process Look Like?<\/h2>\n
\n
What Special Considerations Apply to Older Adults?<\/h2>\n
How Do Mental Health Conditions Affect Eligibility?<\/h2>\n
What Lab Abnormalities Affect Eligibility?<\/h2>\n
FAQ<\/h2>\n
Can I Get Semaglutide If My BMI Is 25?<\/h3>\n
Does PCOS Qualify Me as a Comorbidity at BMI 27-29?<\/h3>\n
What If I Have a Thyroid Nodule but No Cancer History?<\/h3>\n
Can I Take Semaglutide If I Had Gallbladder Surgery?<\/h3>\n
Is Semaglutide Safe with Antidepressants?<\/h3>\n
Will My Provider Check Labs Before Prescribing?<\/h3>\n
What If My Insurance Won’t Cover Labs?<\/h3>\n
Related Articles<\/h2>\n
\n